News

TGD001 receives Orphan Drug Designation in Europe

July 29, 2024

TargED Biopharmaceuticals is thrilled to announce that the European Medicines Agency has granted Orphan Drug Designation for their innovative therapy, TGD001! This first-in-class thrombolytic is set to make a significant impact in the treatment of Thrombotic Thrombocytopenic Purpura (TTP).

Download the full article